ORCID Profile
0000-0002-9027-7411
Current Organisation
University of Adelaide
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Ovid Technologies (Wolters Kluwer Health)
Date: 28-04-2023
Publisher: Longwoods Publishing
Date: 20-02-2018
Publisher: Wiley
Date: 14-04-2015
Publisher: CMA Joule Inc.
Date: 17-10-2017
Publisher: Ovid Technologies (Wolters Kluwer Health)
Date: 09-2017
Publisher: Elsevier BV
Date: 07-2017
DOI: 10.1111/AJT.14275
Abstract: Inclusion of compatible living donor and recipient pairs (CPs) in kidney paired donation (KPD) programs could increase living donor transplantation. We introduce the concept of a reciprocity-based strategy in which the recipient of a CP who participates in KPD receives priority for a repeat deceased donor transplant in the event their primary living donor KPD transplant fails, and then we review the practical and ethical considerations of this strategy. The strategy limits prioritization to CPs already committed to living donation, minimizing the risk of unduly influencing donor behavior. The provision of a tangible benefit independent of the CP's actual KPD match avoids many of the practical and ethical challenges with strategies that rely on finding the CP recipient a better-matched kidney that might provide the CP recipient a future benefit to increase KPD participation. Specifically, the strategy avoids the potential to misrepresent the degree of future benefit of a better-matched kidney to the CP recipient and minimizes delays in transplantation related to finding a better-matched kidney. Preliminary estimates suggest the strategy has significant potential to increase the number of living donor transplants. Further evaluation of the acceptance of this strategy by CPs and by waitlisted patients is warranted.
Publisher: EMBO
Date: 04-12-2014
Publisher: Ovid Technologies (Wolters Kluwer Health)
Date: 04-2017
Publisher: AMPCo
Date: 09-09-2019
DOI: 10.5694/MJA2.50333
Publisher: Cambridge University Press (CUP)
Date: 14-06-2019
DOI: 10.1017/CYL.2019.10
Publisher: Elsevier BV
Date: 10-2014
Publisher: Oxford University Press (OUP)
Date: 16-11-2015
DOI: 10.1093/JLB/LSV038
Publisher: Ovid Technologies (Wolters Kluwer Health)
Date: 15-11-2019
Publisher: Elsevier BV
Date: 09-2014
Publisher: CMA Joule Inc.
Date: 14-11-2016
DOI: 10.1503/CMAJ.160752
Publisher: Elsevier BV
Date: 09-2016
DOI: 10.1016/J.JCF.2016.03.006
Abstract: The cystic fibrosis drug, Kalydeco, has attracted attention both for its effectiveness in particular CF patients and its substantial price tag. An analysis of newspaper portrayals of Kalydeco provides an opportunity to examine how policy issues associated with rare diseases and orphan drugs are being represented in the popular press. We conducted a content analysis of 203 newspaper articles in Canada and the U.S. that mention Kalydeco. Articles were analyzed for their main frame, discussion of Kalydeco, including issues of drug development, patient access, and reimbursement, and overall tone. In Canadian newspaper coverage, 77.4% of articles were framed as human interest stories featuring in idual patients seeking public funding for Kalydeco, yet only 7.5% mentioned any budgetary limitations in doing so. In contrast, U.S. newspaper coverage was framed as a financial/economic story in 43.1% of articles and a medical/scientific story in 27.8%. Newspaper coverage varied significantly between Canada, where Kalydeco is predominantly a story about increasing patient access through full government funding, and the U.S., where Kalydeco is largely a financial story about the economic impact of Kalydeco. The difference in coverage may be due to differences in public funding between the healthcare systems of these two countries.
Publisher: Public Library of Science (PLoS)
Date: 13-09-2022
DOI: 10.1371/JOURNAL.PONE.0271401
Abstract: The brown dog tick ( Rhipicephalus sanguineus ) is the most prevalent tick in the world and a well-recognized vector of many pathogens affecting dogs and occasionally humans. Pathogens exploit tick salivary molecules for their survival and multiplication in the vector and transmission to and establishment in the hosts. Tick saliva contains various non-proteinaceous substances and secreted proteins that are differentially produced during feeding and comprise of inhibitors of blood congealing and platelet aggregation, vasodilatory and immunomodulatory substances, and compounds preventing itch and pain. One of these proteins is Evasin-1, which has a high binding affinity to certain types of chemokines. The binding of Evasin-1 to chemokines prevents the detection and immune response of the host to R . sanguineus , which may result in the successful transmission of pathogens. In this study, we screened potential Evasin-1 inhibitor based on the pharmacophore model derived from the binding site residues. Hit ligands were further screened via molecular docking and virtual ADMET prediction, which resulted in ZINC8856727 as the top ligand (binding affinity: -9.1 kcal/mol). Molecular dynamics simulation studies, coupled with MM-GBSA calculations and principal component analysis revealed that ZINC8856727 plays a vital role in the stability of Evasin-1. We recommend continuing the study by developing a formulation that serves as a potential medicine aid immune response during R . sanguineus infestation.
No related grants have been discovered for Maeghan Toews.